Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib.
Fiche publication
Date publication
décembre 2015
Journal
Journal of cachexia, sarcopenia and muscle
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier, Pr HOEFFEL Christine
Tous les auteurs :
Moryoussef F, Dhooge M, Volet J, Barbe C, Brezault C, Hoeffel C, Coriat R, Bouché O
Lien Pubmed
Résumé
Imatinib is a long-term, oral, targeted therapy for high-risk resected and advanced gastrointestinal stromal tumours (GIST). It is known that sarcopenia affects prognosis and treatment tolerance in patients with various solid cancers. We analysed lumbar skeletal muscle index changes in imatinib-treated GIST patients. Imatinib tolerance was also assessed to evaluate the influence of pre-treatment sarcopenia.
Mots clés
Body composition, C-kit inhibitors, Gastrointestinal stromal tumours, Imatinib, Sarcopenia, Toxicity
Référence
J Cachexia Sarcopenia Muscle. 2015 Dec;6(4):343-50